drugset / Trial / NCT02187159

Treatment of Pain Associated With Fibromyalgia

NCT02187159

Phase 3 Completed 1270 enrolled Daiichi Sankyo Syneos Health · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in participants receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the participant that best describes his or her worst pain over the previous 24 hours.

Timeline

Start
2014-11
Primary completion
2016-07-07
Completion
2016-07-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirogabalin Small molecule 15 mg Oral
Comparator Pregabalin Small molecule 150 mg Oral

Indications